hackint0sh/New-Dataset huggingface dataset:
Methods: Participants were assigned randomly into two groups, ST (multicomponent physical exercise) and DT training (multicomponent physical exercise + cognitive tasks). Both groups performed the exercise three times per week for 1 month. Short Physical Performance Battery (SPPB), handgrip strength, Barthel Index and Montreal Cognitive Assessment (MoCA) were used to assess physical and cognitive performance, respectively. Variables were measured at the beginning (V1),at the end of the exercise (V2), as well as one month later (V3). Paired Student's t-test and lineal logistic regressions models were used to explore the effect of the exercise interventions. conditions: Functional Movement Disorder conditions: Fragility studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Assignment primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Although blinding is not possible for participants in exercise-intervention research, the outcome assessors and data analysts were masked to group assignments. The study was unblinded after the statistical analyses were completed. whoMasked: PARTICIPANT count: 24 type: ACTUAL name: Single-Task name: Dual-Task measure: Short Physical Performance Battery (SPPB) measure: Montreal Cognitive Assessment (MoCA) measure: Barthel Index measure: Isometric Handgrip Strength (IHS) measure: Immobility Syndrome Scale sex: ALL minimumAge: 65 Years maximumAge: 75 Years stdAges: OLDER_ADULT facility: Universidad de las Americas city: Santiago de Chile state: Santiago zip: 7750495 country: Chile lat: -33.45694 lon: -70.64827 hasResults: False
nctId: NCT06361602 id: SYSKY-2023-1015-01 briefTitle: Exploring the Effectiveness and Factors Affecting the Collection of Single Nucleated Cells From Different Volunteers acronym: SYX-AN-01 overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-05-01 date: 2027-05-01 date: 2024-04-12 date: 2024-04-12 name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University class: OTHER briefSummary: 1. 80 cases of healthy donors were subjected to peripheral blood single nucleated cells (PBMC) collection and analyzed the effects of age, body mass index (BMI), blood routine indexes before collection, collection of circulating blood volume, volume of processed blood and the number of circulations, etc., on the PBMC obtained from both men and women, and explored the effects of PBMC collection in different volunteers and the factors affecting the collection. and the influencing factors.
3. From the screening of volunteers, PBMC collection and transportation conditions and other specific details of the operation, risk assessment and the establishment of a safe operation standard process, for the hospital to carry out subsequent clinical trials of immune cell therapy to provide an effective reference. conditions: Observational Study studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 80 type: ESTIMATED name: inapplicable measure: Exploring the effectiveness and factors affecting the collection of single nucleated cells from different volunteers sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06361589 id: EK2023003-1 briefTitle: Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients overallStatus: RECRUITING date: 2024-05-01 date: 2026-11-01 date: 2028-11-01 date: 2024-04-12 date: 2024-04-12 name: Sichuan Cancer Hospital and Research Institute class: OTHER briefSummary: This study was a multicenter, prospective, non-interventional clinical study that included first-line and late-line patients with advanced non-small cell lung cancer with ALK fusions treated with the third generation ALK-TKI lorlatinib until disease progression, intolerable toxicity, investigator or subject decision to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death. Clinical pathology including sex, age, ALK mutation status at diagnosis, and clinical stage at diagnosis were collected from medical records. Physical condition as assessed by ECOG-PS before administration of lorlatinib was also recorded. Treatment information was obtained from the records, including dose and timing of ALK-TKI therapy and tumor response, number of prior systemic lines of therapy, and local treatment modalities such as radiotherapy and surgery. Quality of life based on the EORTC QLQ C30+LC29 scale (plus the EORTC QLQ BN20 scale in patients with brain/meningeal metastases) was performed at baseline and at each follow-up point. This study will use REDCap platform to collect and manage the study data information of multi-center patients. conditions: ALK-positive Non-small Cell Lung Cancer conditions: Real World Study studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Lorlatinib measure: PFS measure: OS measure: ORR measure: AE measure: PRO1 measure: PRO2 measure: PRO3 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sichuan cancer hospital status: RECRUITING city: Chengdu state: Sichuan zip: 610000 country: China name: Juan Li, MD role: CONTACT phone: 13880276636 email: dr.lijuan@hotmail.com lat: 30.66667 lon: 104.06667 hasResults: False
nctId: NCT06361576 id: CA209-1443 briefTitle: Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada overallStatus: COMPLETED date: 2023-09-05 date: 2024-01-25 date: 2024-01-25 date: 2024-04-12 date: 2024-04-12 name: Bristol-Myers Squibb class: INDUSTRY briefSummary: The purpose of this observational study is to describe the demographics, and disease characteristics of participants with metastatic upper gastrointestinal cancer, along with the treatment characteristics of these patients when treated with nivolumab. conditions: Upper Gastrointestinal Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 700 type: ACTUAL name: Nivolumab measure: Particpant sociodemographics measure: Participant Eastern Cooperative Oncology Group (ECOG) score measure: Participant HER2 status measure: Participant comorbidities measure: Participant tumour location measure: Participant treatment history measure: Initial nivolumab dosage prescribed to participants measure: Number of nivolumab treatments received by participants measure: Planned combination chemotherapy treatment measure: Nivolumab treatment initiation date measure: Nivolumab dosage modification measure: Participant treatment duration measure: Reason for participant discharge measure: Participant adverse events (AEs) measure: Management of participant adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bayshore Specialty Rx Ltd. city: Mississauga state: Ontario zip: L5K 2L3 country: Canada lat: 43.5789 lon: -79.6583 hasResults: False
nctId: NCT06361563 id: CA209-1442 briefTitle: Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada overallStatus: COMPLETED date: 2023-09-05 date: 2024-01-25 date: 2024-01-25 date: 2024-04-12 date: 2024-04-12 name: Bristol-Myers Squibb class: INDUSTRY briefSummary: The purpose of this observational study is to describe the patient, disease and treatment characteristics of eligible participants with upper gastrointestinal cancer treated with adjuvant nivolumab. conditions: Upper Gastrointestinal Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 250 type: ACTUAL name: Nivolumab measure: Participant sociodemographics measure: Participant Eastern Cooperative Oncology Group (ECOG) score measure: Participant histology results measure: Participant comorbidities measure: Participant tumour location measure: Date of tumour resection measure: Participant primary upper gastrointestinal cancer diagnosis measure: Initial nivolumab dosage prescribed to participants measure: Number of nivolumab treatments received measure: Nivolumab dosage modification measure: Nivolumab treatment duration measure: Reason for participant discharge measure: Participant adverse events (AEs) measure: Management of participant adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bayshore Specialty Rx Ltd. city: Mississauga state: Ontario zip: L5K 2L3 country: Canada lat: 43.5789 lon: -79.6583 hasResults: False
nctId: NCT06361550 id: AYTO_SALAMANCA_001 briefTitle: Nutritional Status Assessment and Dietary Recommendations Program (VENREDI) overallStatus: RECRUITING date: 2023-11-02 date: 2025-06-30 date: 2025-12-30 date: 2024-04-12 date: 2024-04-12 name: University of Salamanca class: OTHER name: Ayuntamiento de Salamanca briefSummary: Introduction: The Mediterranean diet has been related to beneficial effects in the prevention of cardiovascular diseases and other chronic pathologies related to diet, including some types of cancer. Specifically in the elderly population, it has been observed that the Mediterranean diet is inversely associated with all causes of mortality and that the greater the adherence to this type of diet, the lower the mortality in elderly adults.
An initial and post-intervention evaluation will be carried out after 3 months so that both groups can study the change variables related to Adherence to the Mediterranean Diet \[Mediterranean Diet Adherence Questionnaire (MEDAS)\], physical activity \[Short physical performance battery (SPPB)\], sleep quality (ATENAS questionnaire) and assessment of cognitive function (MOCA questionnaire). conditions: Adherence to the Mediterranean Diet studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 200 type: ESTIMATED name: VENREDI group name: Health education measure: Adherence to the Mediterranean Diet measure: Physical activity measure: Sleep Quality measure: Cognitive function sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rosario Alonso Domínguez status: RECRUITING city: Salamanca zip: 37007 country: Spain name: Rosario Alonso Domínguez, PhD role: CONTACT phone: 0034923294500 phoneExt: 3280 email: ralonsod@usal.es lat: 40.96882 lon: -5.66388 hasResults: False
nctId: NCT06361537 id: CONE-02 briefTitle: Phase 3 Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-12 date: 2025-12 date: 2024-04-12 date: 2024-04-12 name: Octapharma class: INDUSTRY briefSummary: Prospective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks conditions: Acute Hereditary Angio Edema studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 124 type: ESTIMATED name: OCTA-C1-INH name: Placebo measure: Time (h) to beginning of unequivocal symptom relief at the defining site in blinded participants. measure: Percentage of participants responding to treatment measure: Time to beginning of unequivocal symptom relief at all sites involved measure: Changes in symptom severity at the defining site by VAS severity rating sex: ALL minimumAge: 2 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06361524 id: 44967 id: 5F32HL143916 type: NIH link: https://reporter.nih.gov/quickSearch/5F32HL143916 id: 856341 type: OTHER_GRANT domain: American Heart Association briefTitle: Gut Microbiome Profiling in Patients With Chronic Heart Failure overallStatus: ENROLLING_BY_INVITATION date: 2018-08-01 date: 2028-12 date: 2028-12 date: 2024-04-12 date: 2024-04-12 name: Stanford University class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) name: American Heart Association briefSummary: The goal of this observational study is to learn about the composition and function of the gut microbiome in adults with chronic heart failure with reduced ejection fraction. The main questions the study aims to answer are:
2. How do these changes relate to heart failure disease severity and complications? conditions: Heart Failure With Reduced Ejection Fraction conditions: Nonischemic Cardiomyopathy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED measure: Advanced heart failure-associated microbiome signatures measure: Temporal changes in the gut microbiome community composition in chronic heart failure measure: Comprehensive longitudinal metabolome profile in chronic heart failure measure: Comprehensive longitudinal cytokine profile in chronic heart failure measure: Longitudinal change in New York Heart Association (NYHA) functional class measure: Longitudinal change in the self-reported functional status sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stanford University city: Stanford state: California zip: 94305-5210 country: United States lat: 37.42411 lon: -122.16608 hasResults: False
nctId: NCT06361511 id: 2023H0284 briefTitle: The Foods & Oil to Repair, Correct and Enhance Strength (FORCES) Study overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2029-05-01 date: 2030-05-01 date: 2024-04-12 date: 2024-04-12 name: Ohio State University class: OTHER name: National Institutes of Health (NIH) briefSummary: The proposed research is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in muscle strength, volume, fatigue resistance, and mobility in older adults after daily consumption of 12g of linoleic acid-rich oil. conditions: Sarcopenia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 66 type: ESTIMATED name: High Linoleic Acid Foods name: High Oleic Acid Foods measure: Changes is leg extensor muscle strength measure: Changes in quadriceps muscle volume measure: Change in maximum leg press strength measure: Change in leg fatiguability measure: Change in muscle mitochondria function measure: Changes in cardiolipin species measure: Changes in grip strength measure: Changes in gait speed measure: Changes in chair rise time measure: Changes in stair climb power measure: Change in short physical performance battery score measure: change in blood fatty acids measure: Association of changes in plasma linoleic acid with muscle function measure: Association of changes in plasma linoleic acid with muscle strength measure: Association of changes in plasma linoleic acid with muscle volume measure: Association of changes 4-LA-cardiolipin with muscle function measure: Association of changes 4-LA-cardiolipin with muscle strength measure: Association of changes 4-LA-cardiolipin with muscle volume measure: Association of changes mitochondria function with muscle volume. measure: Association of changes mitochondria function with muscle function measure: Association of changes mitochondria function with muscle strength. sex: ALL minimumAge: 65 Years maximumAge: 80 Years stdAges: OLDER_ADULT facility: The Ohio State University city: Columbus state: Ohio zip: 43210 country: United States lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06361498 id: 23-3115 briefTitle: Ultrasound for Evaluation of Percutaneous G-tube Position overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-03 date: 2025-03 date: 2024-04-12 date: 2024-04-12 name: University of North Carolina, Chapel Hill class: OTHER briefSummary: The goal of this clinical trial is to compare using ultrasound imaging to look at the position of the gastrostomy tube (GT) against fluoroscopic imaging in pediatric patients who had a recent GT tube replacement.
Participants will be imaging using ultrasound to assess GT positioning before their standard of care fluoroscopic imaging. conditions: Gastrostomy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 10 type: ESTIMATED name: Ultrasound Imaging measure: Proportion of Ultrasound that Agree with Fluoroscopy with Respect to Identifying the GT Location measure: Sensitivity of ultrasound (US) to determine the visualization of GT leakage measure: Specificity of ultrasound (US) to determine the visualization of GT leakage measure: Duration of ultrasound (US) to complete evaluation of GT position sex: ALL maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: University of North Carolina at Chapel Hill city: Chapel Hill state: North Carolina zip: 27599 country: United States name: Hannah P Mignosa-Martin role: CONTACT phone: 919-843-1670 email: hannah_mignosa@med.unc.edu name: Desma Jones role: CONTACT phone: 9198439463 email: desma_jones@med.unc.edu name: William Pryor, MD role: PRINCIPAL_INVESTIGATOR lat: 35.9132 lon: -79.05584 hasResults: False
nctId: NCT06361485 id: 011624 briefTitle: Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain overallStatus: RECRUITING date: 2024-03-25 date: 2027-03-31 date: 2028-04-01 date: 2024-04-11 date: 2024-04-11 name: R3 Stem Cell class: INDUSTRY name: R3 Medical Research briefSummary: This is a Pilot Study that is an open label, prospective, non-controlled study in which the safety and feasibility of Wharton's Jelly (WJ) allograft will be evaluated in 100 participants suffering with low back pain. conditions: Low Back Pain studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective, open label, non-controlled Pilot study primaryPurpose: TREATMENT masking: NONE maskingDescription: Open Label count: 100 type: ESTIMATED name: Lumbar Injections with 10cc's of Wharton's Jelly Allograft measure: C-reactive protein measure: Erythrocyte sedimentation rate measure: Alanine transaminase (ALT) measure: Aspartate transaminase (AST) measure: Alkaline phosphatase (ALP) measure: Albumin measure: Creatinine measure: Blood Urea Nitrogen (BUN) measure: 36-Item Short Form Survey (SF-36) measure: Numerical Pain Rating Scale (NPRS) measure: Oswestry disability index (ODI) measure: Roland Morris disability questionnaire (RMQ) measure: The Patient-specific functional scale (PSFS) sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: R3 Anti Aging Scottsdale status: RECRUITING city: Scottsdale state: Arizona zip: 85262 country: United States name: David Greene, MD, PhD, MBA role: CONTACT phone: 480-306-6256 email: dgreene@r3medicalresearch.com name: Sabrina Solt, NMD role: PRINCIPAL_INVESTIGATOR lat: 33.50921 lon: -111.89903 facility: R3 Anti Aging Beverly Hills status: RECRUITING city: Beverly Hills state: California zip: 90210 country: United States name: Kathleen Francesca, BA role: CONTACT phone: 424-382-1074 email: kfrancesca@r3stemcell.com name: Neville Campbell, MD role: PRINCIPAL_INVESTIGATOR lat: 34.07362 lon: -118.40036 facility: Scheer Medical Wellness status: RECRUITING city: New York state: New York zip: 10036 country: United States name: Alexandre Scheer, MD role: CONTACT phone: 646-762-9499 email: ascheer911@gmail.com name: Alexandre Scheer, MD role: PRINCIPAL_INVESTIGATOR lat: 40.71427 lon: -74.00597 facility: Dr. Duc (Steve) Le, MD status: RECRUITING city: Cleveland state: Texas zip: 77327 country: United States name: Steve Le, MD role: CONTACT phone: 281-593-1500 email: ducstevele@gmail.com name: Steve Le, MD role: PRINCIPAL_INVESTIGATOR lat: 31.67682 lon: -99.25367 hasResults: False
nctId: NCT06361472 id: 11695 briefTitle: Contextual Factors-Enriched Standard Care on Mechanical Neck Pain overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-08-31 date: 2025-11-30 date: 2024-04-11 date: 2024-04-15 name: Universidad Nacional de la Matanza class: OTHER briefSummary: The primary purpose of this study will be to determine if a CFs-Enriched Standard Care approach is an effective treatment for mechanical neck pain in terms of reducing pain and improving function. We hypothesize that a 4-week CFs-Enriched Standard Care approach will be superior to Standard Care alone in terms of patient-reported disability and pain, with measurements conducted using the Northwick Park Neck Pain Questionnaire and the Numeric Pain Rating Scale, respectively.
The primary outcomes will encompass changes in Pain and Disability after 4 weeks of treatment, with a follow-up reassessment at week 12 post-treatment. Secondary outcomes will include changes in Active Range of Motion, Global Rating of Change, and Satisfaction with treatment. The change between groups after treatment and at the 12-week follow-up will be reported for all outcomes, considering the difference from scores recorded at baseline. conditions: Neck Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The ContextualizAR trial is designed as a two-arm, randomized, controlled, and blinded assessor superiority trial conducted at a single center. Patients will be allocated to one of two groups: a CFs+SC group and the SC group. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Due to the nature of the study, blinding of both therapists and patients will not be feasible. However, to uphold the scientific validity of the study, specific descriptors and methodological details, such as terms like "placebo" or "CFs," have been intentionally excluded from the consent disclosure. To prevent any potential bias in participants' perceptions, information regarding the potential involvement of CFs in outcomes will not be provided. Instead, participants will be informed that the study aims to assess changes resulting from standard treatment for MNP. The person in charge of data statistical analysis (FV) and the evaluators who will assess all participants' pre- and post-intervention assessments (MLL and AR) will be blinded to the allocated intervention. whoMasked: OUTCOMES_ASSESSOR count: 94 type: ESTIMATED name: Standard Care name: Contextual Factors measure: Neck Pain Intensity measure: Neck Disability measure: Active Range of Movement measure: Global Rating of Change measure: Satisfaction with treatment measure: Expectations measure: Credibility sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False